CLDI
Calidi Biotherapeutics, Inc. (CLDI) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (D-). The rating has held at C- for 4 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | B+ (3.7) | C+ (2.5) | D- (0.9) | D- (0.8) | C+ (2.6) | C- (2.1) |
| 2026-11-04 | B+ (3.7) | C+ (2.5) | D- (0.9) | D- (0.7) | C+ (2.7) | C- (2.1) |
| 2026-10-28 | B+ (3.7) | C+ (2.5) | D- (0.9) | F (0.7) | C+ (2.7) | C- (2.1) |
| 2026-10-21 | B+ (3.7) | C+ (2.5) | D- (0.9) | F (0.7) | C+ (2.6) | C- (2.1) |
| 2026-10-14 | C+ (2.5) | C+ (2.5) | D- (0.9) | D- (0.7) | C+ (2.6) | C- (1.9) |